Choroidal neovascularization secondary to tuberculosis: Presentation and management.

Am J Ophthalmol Case Rep

USC Roski Eye Institute, Keck School of Medicine of the University of Southern California, 1333 San Pablo Street, Suite 218, 90033, Los Angeles, CA, USA.

Published: April 2017

Purpose: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management.

Observations: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease-the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent.

Conclusions And Importance: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758031PMC
http://dx.doi.org/10.1016/j.ajoc.2016.12.025DOI Listing

Publication Analysis

Top Keywords

tuberculous chorioretinitis
12
three patients
12
choroidal neovascularization
8
cnv
8
intraocular inflammation
8
macular cnv
8
patients active
8
anti-tuberculosis medications
8
medications oral
8
oral corticosteroids
8

Similar Publications

Purpose: To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib.

Methods: Case report.

Results: A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib for metastatic renal cell carcinoma.

View Article and Find Full Text PDF

A 61-year-old woman had worsening vision for 12 years associated with progressive patchy macular chorioretinal atrophy. There was latent tuberculosis and angioid streaks. Testing revealed a pathogenic variant of PRPH2 and a heterozygous ABCC6 variant.

View Article and Find Full Text PDF

Purpose: To study and compare the clinical characteristics and outcome of ocular syphilis between HIV positive and HIV negative patients.

Methods: Retrospective hospital-based case series from a tertiary eye care hospital in India. Patients with uveitis and positive syphilis serology were included.

View Article and Find Full Text PDF

Case Report: Disseminated Tuberculosis After Kidney Transplantation.

Am J Trop Med Hyg

September 2024

Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Article Synopsis
  • Tuberculosis (TB) poses a serious risk for solid organ transplant (SOT) recipients, particularly affecting kidney transplant patients, though there’s limited data on this.
  • In immunocompromised individuals, TB can present in unusual ways, so healthcare providers need to be vigilant, especially if the patient has lived in areas where TB is common.
  • A notable case describes a 54-year-old Filipino woman who developed severe TB complications, underscoring the importance of prevention, diagnosis, and treatment in managing this potentially deadly and curable disease.
View Article and Find Full Text PDF

Background: Tuberculosis (TB)-immunoreactivity, measured in vivo (tuberculin skin test (TST)) or in vitro (interferon gamma release assay (IGRA)), can be found in latent, active or even following clearance of TB infection. In this case-control study, we compared the systemic and ocular outcomes between patients with or without TB-immunoreactivity, who received immunomodulatory therapy (IMT) for non-infectious uveitis.

Methods: We retrospectively reviewed charts of patients with (cases) or without (controls) TB-immunoreactivity (TST±IGRA), who received conventional IMT for ≥6 months, for the treatment of non-infectious uveitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!